← Back to Treatments
🏅 FDA Orphan Designation

Deflazacort Oral Suspension

DEFLAZACORT

Manufacturer: Zydus Pharmaceuticals (USA) Inc.

Indicated for:
Duchenne muscular dystrophyOrphan

FDA-Approved Indications (1)

Duchenne muscular dystrophyOrphan Designation

1 INDICATIONS AND USAGE Deflazacort oral suspension is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Additional pediatric use information is ap…

Indications & Usage

1 INDICATIONS AND USAGE Deflazacort oral suspension is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Additional pediatric use information is approved for PTC Therapeutics, Inc.'s Emflaza™ (deflazacort) oral suspension. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information . Deflazacort oral suspension is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older ( 1 )

💙 Support Programs

View all →
Deflazacort Oral Suspension
PTC
Copay card ↗Apply ↗
Deflazacort
PTC
Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.